Report from Asia - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Report from Asia
Global pharmaceutical companies have much to gain in Asia, and the good news is that it's a two-way street. Firms based in Asia are also expected to grow at the global level.

Pharmaceutical Technology
Volume 34, Issue 12, pp. 18-19

Big Pharma gains

Still, many pharmaceutical companies have yet to stamp their presence in Asia. Only the larger firms seem to have made real gains. Earlier this year, Pfizer (New York) commented that it is expecting its China business to grow by at least 25%. It has planned to forge more partnerships and expand its team of representatives, many of whom are trained doctors, from 2300 in 177 cities to 3200 in 252 cities by 2011. It is also teaming up with Japan's Takeda Pharmaceutical (Tokyo) to sell the latter's blockbuster Actos diabetes drug in China. On the other hand, Novartis' (Basel) made a $1 billion research and development investment in China and took an 85% stake in a privately held vaccine company in China.

"Currently, many foreign firms are still playing the catch-up game and exploring ways to enter the Asian market. Some are considering the M&As option as a means to increase presence in Asia," says Jan Williem Eleveld, vice-president of consulting and services for the Asia–Pacific at IMS Health.

In the long run, local and foreign companies are likely to benefit from global partnerships in the Asian region. As Pieter de Geus, vice-president of strategic business development at DSM Pharma Cluster (Heerlen, The Netherlands), explains, "Generally, professional sales and marketing of MNCs [multinational corporations] will elevate the overall market practices for local companies. The [intellectual property] protection environment will also improve [in Asia] as there will be a push for sophisticated and efficient research and development requirements." He noted that the presence of global firms will also fuel the generic-drug market.

Eleveld adds, "There will be a positive development for patients and governments as foreign firms will support the availability of innovative medicines to treat unmet medical needs in the region. This will also present an opportunity for local companies to assist their foreign counterparts through joint marketing collaborations."

Interestingly, Asian companies are making their presence known in overseas markets although the industry has yet to see a definite regional or global player. Some attempts to increase overseas presence include Simcere's (Nanjing, Jiangsu) in-licensing of an oncology drug and clinical-trial program in the United States, and the China National Biotech Group's (Beijing) attempt to become a worldwide vaccine manufacturing leader.

Mooney says, "Asian companies are expected to perform well in overseas markets. We can certainly expect them to gain dominance over time and to come up with products that are innovative at lower price points that will cater to both US and European markets."

Jane Wan is a freelance writer based in Singapore.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here